Deutsche Bank AG Takes Position in Krystal Biotech, Inc. $KRYS

Deutsche Bank AG acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 31,836 shares of the company's stock, valued at approximately $11,832,000. Deutsche Bank AG owned 0.11% of Krystal Biotech at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new stake in Krystal Biotech in the first quarter worth approximately $34,000. Greenline Wealth Management LLC acquired a new position in shares of Krystal Biotech during the 4th quarter valued at $34,000. Danske Bank A S acquired a new position in shares of Krystal Biotech during the 3rd quarter valued at $35,000. UMB Bank n.a. raised its stake in shares of Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after buying an additional 37 shares in the last quarter. Finally, Global Retirement Partners LLC raised its stake in shares of Krystal Biotech by 788.9% in the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company's stock worth $39,000 after buying an additional 142 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company's stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the business's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 51,642 shares of company stock valued at $16,471,923. Company insiders own 13.10% of the company's stock.

Krystal Biotech Price Performance

Shares of KRYS opened at $346.58 on Friday. Krystal Biotech, Inc. has a one year low of $136.73 and a one year high of $382.54. The company has a 50-day moving average of $347.03 and a two-hundred day moving average of $301.40. The stock has a market cap of $10.26 billion, a price-to-earnings ratio of 43.43 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The business had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Wall Street Analyst Weigh In

KRYS has been the subject of several research analyst reports. Wall Street Zen lowered Krystal Biotech from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. Evercore reissued an "outperform" rating and issued a $300.00 price target on shares of Krystal Biotech in a report on Tuesday, May 5th. Chardan Capital raised shares of Krystal Biotech to a "strong-buy" rating in a research note on Monday, August 3rd. Bank of America boosted their target price on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a "buy" rating in a report on Tuesday, July 14th. Finally, Weiss Ratings lowered shares of Krystal Biotech from a "buy (b)" rating to a "buy (b-)" rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Krystal Biotech has a consensus rating of "Moderate Buy" and a consensus target price of $365.40.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source